Bench-to-bedside review: Sepsis, severe sepsis and septic shock - does the nature of the infecting organism matter?

被引:48
作者
Gao, Hongmei [1 ]
Evans, Timothy W. [1 ]
Finney, Simon J. [1 ]
机构
[1] Royal Brompton Hosp, Adult Intens Care Unit, London SW3 6NP, England
关键词
D O I
10.1186/cc6862
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
International guidelines concerning the management of patients with sepsis, septic shock and multiple organ failure make no reference to the nature of the infecting organism. Indeed, most clinical signs of sepsis are nonspecific. In contrast, in vitro data suggest that there are mechanistic differences between bacterial, viral and fungal sepsis, and imply that pathogenetic differences may exist between subclasses such as Gram-negative and Gram-positive bacteria. These differences are reflected in different cytokine profiles and mortality rates associated with Gram-positive and Gram-negative sepsis in humans. They also suggest that putative anti-mediator therapies may act differently according to the nature of an infecting organism. Data from some clinical trials conducted in severe sepsis support this hypothesis. It is likely that potential new therapies targeting, for example, Toll-like receptor pathways will require knowledge of the infecting organism. The advent of new technologies that accelerate the identification of infectious agents and their antimicrobial sensitivities may allow better tailored anti-mediator therapies and administration of antibiotics with narrow spectra and known efficacy.
引用
收藏
页数:6
相关论文
共 59 条
[11]   Bacteremia and severe sepsis in adults: A multicenter prospective survey in ICUs and wards of 24 hospitals [J].
BrunBuisson, C ;
Doyon, F ;
Carlet, J ;
Bedock, B ;
Annonay, CH ;
Valente, E ;
Lescale, O ;
Misset, B ;
Charbonneau, P ;
Vergnaud, M ;
Cohen, R ;
Coloignier, M ;
Frances, JL ;
Combes, A ;
Duval, O ;
Dellamonica, P ;
Descamps, JM ;
Domart, Y ;
Galiacy, JL ;
Gouin, F ;
Guivarch, G ;
Hennequin, C ;
Krajevitch, A ;
Delmas, P ;
Holzapfel, L ;
Lepeu, G ;
Loirat, P ;
Thaler, F ;
Knani, L ;
Mercier, JC ;
Mouton, Y ;
Libbrecht, E ;
Offenstadt, G ;
Pinaud, M ;
Pinsart, M ;
Girou, E ;
Portier, H ;
Grappin, M ;
Rebeix, MT ;
Regnier, B ;
Gachot, B ;
Ricome, JL ;
Sollet, JP ;
Mentec, H ;
Tempelhoff, G ;
Beuret, P ;
Lepoutre, A .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1996, 154 (03) :617-624
[12]   Identification and characterization of bacterial pathogens causing bloodstream infections by DNA microarray [J].
Cleven, Berit E. E. ;
Palka-Santini, Maria ;
Gielen, Joerg ;
Meembor, Salima ;
Kroenke, Martin ;
Krut, Oleg .
JOURNAL OF CLINICAL MICROBIOLOGY, 2006, 44 (07) :2389-2397
[13]   INTERSEPT: An international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis [J].
Cohen, J ;
Carlet, J .
CRITICAL CARE MEDICINE, 1996, 24 (09) :1431-1440
[14]   Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock [J].
Dellinger, RP ;
Carlet, JM ;
Masur, H ;
Gerlach, H ;
Calandra, T ;
Cohen, J ;
Gea-Banacloche, J ;
Keh, D ;
Marshall, JC ;
Parker, MM ;
Ramsay, G ;
Zimmerman, JL ;
Vincent, JL ;
Levy, MM .
CRITICAL CARE MEDICINE, 2004, 32 (03) :858-873
[15]   PLATELET-ACTIVATING-FACTOR RECEPTOR ANTAGONIST BN-52021 IN THE TREATMENT OF SEVERE SEPSIS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER CLINICAL-TRIAL [J].
DHAINAUT, JFA ;
TENAILLON, A ;
LETULZO, Y ;
SCHLEMMER, B ;
SOLET, JP ;
WOLFF, M ;
HOLZAPFEL, L ;
ZENI, F ;
DREYFUSS, D ;
MIRA, JP ;
DEVATHAIRE, F ;
GUINOT, P .
CRITICAL CARE MEDICINE, 1994, 22 (11) :1720-1728
[16]   Is Panton-Valentine leucocidin associated with the pathogenesis of Staphylococcus aureus bacteraemia in the UK? [J].
Ellington, Matthew J. ;
Hope, Russell ;
Ganner, Mark ;
Ganner, Marjorie ;
East, Claire ;
Brick, Geraldine ;
Kearns, Angela M. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (02) :402-405
[17]   Molecular characterization of the acute inflammatory response to infections with gram-negative versus gram-positive bacteria [J].
Feezor, RJ ;
Oberholzer, C ;
Baker, HV ;
Novick, D ;
Rubinstein, M ;
Moldawer, LL ;
Pribble, J ;
Souza, S ;
Dinarello, CA ;
Ertel, W ;
Oberholzer, A .
INFECTION AND IMMUNITY, 2003, 71 (10) :5803-5813
[18]   Treatment of severe systemic inflammatory response syndrome and sepsis with a novel bradykinin antagonist, deltibant (CP-0127) - Results of a randomized, double-blind, placebo-controlled trial [J].
Fein, AM ;
Bernard, GR ;
Criner, GJ ;
Fletcher, EC ;
Good, JT ;
Knaus, WA ;
Levy, H ;
Matuschak, GM ;
Shanies, HM ;
Taylor, RW ;
Rodell, TC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (06) :482-487
[19]   Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein [J].
Fisher, CJ ;
Agosti, JM ;
Opal, SM ;
Lowry, SF ;
Balk, RA ;
Sadoff, JC ;
Abraham, E ;
Schein, RMH ;
Benjamin, E .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (26) :1697-1702
[20]   RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF PATIENTS WITH SEPSIS SYNDROME - RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
FISHER, CJ ;
DHAINAUT, JFA ;
OPAL, SM ;
PRIBBLE, JP ;
BALK, RA ;
SLOTMAN, GJ ;
IBERTI, TJ ;
RACKOW, EC ;
SHAPIRO, MJ ;
GREENMAN, RL ;
REINES, HD ;
SHELLY, MP ;
THOMPSON, BW ;
LABRECQUE, JF ;
CATALANO, MA ;
KNAUS, WA ;
SADOFF, JC ;
ASTIZ, M ;
CARPATI, C ;
BONE, RC ;
FREIDMAN, B ;
MURE, AJ ;
BRATHWAITE, C ;
SHAPIRO, E ;
MELHORN, L ;
TAYLOR, R ;
KEEGAN, M ;
OBRIEN, J ;
SCHEIN, R ;
PENA, M ;
WASSERLOUF, M ;
OROPELLO, J ;
BENJAMIN, E ;
DELGUIDICE, R ;
EMMANUEL, G ;
LIE, T ;
ANDERSON, L ;
MARSHALL, J ;
DEMAJO, W ;
ROTSTEIN, O ;
FOSTER, D ;
ABRAHAM, E ;
MIDDLETON, H ;
PERRY, C ;
LEVY, H ;
FRY, DE ;
SIMPSON, SQ ;
CROWELL, RE ;
NEIDHART, M ;
STEVENS, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (23) :1836-1843